Full Name
Badiaa Bouzya
Speaker Bio
I am the Cell-Based and Biophysical Innovation Lead at GSK, with over 27 years of experience in the pharmaceutical industry since joining GSK in 1998. In my current role, I lead the innovation and implementation of cell-based assays and biophysical methods across GSK’s Global Supply Chain manufacturing sites. My focus is on advancing analytical performance, efficiency, and compliance by transitioning from in vivo to scientifically robust in vitro approaches, adopting advanced analytical techniques, and enhancing biophysical assay capabilities to align with industry best practices and regulatory standards.
As a global technical lead in analytical science, I oversee the development, validation, and deployement of cutting-edge methods for biological products, establish global standards, and drive harmonization across the GSK network. I collaborate with internal teams and external regulatory bodies to ensure compliance with evolving regulatory requirements, strengthen innovation, and position GSK as a leader in analytical science.
Throughout my career, I have held various leadership positions, including Product & Process Analytics Head, Project Manager and Scientist. My expertise spans preclinical models, vaccinology, virology, molecular biology, in vitro and in vivo assay development, flow cytometry, and bioinformatics tools.
I have contributed to preclinical immunology for viral vaccines, including immunogenicity and efficacy studies, toxicity assessments, and regulatory submissions. My work has supported Phase I/II clinical trials for the vaccines targeting pediatrics and older adults.
I’m author and co-author on several peer-reviewed articles in high-impact journals (Nature Communications, Science Translational Medicine, The Lancet Infectious Diseases, npj Vaccines, ImmunoHorizons) :
- Bouzya B et al. Immunogenicity of an AS01-adjuvanted RSVPreF3 vaccine in animal models. npj Vaccines (2023). doi:10.1038/s41541-023-00729-4.
- Stokes A H et al. Repeated dose toxicity and DART studies of an RSV candidate vaccine in rabbits and rats. International Journal of Toxicology (2021). doi:10.1177/1091581820985782.
- Folschweiller N et al. Reactogenicity, safety, and immunogenicity of chimeric HA influenza split-virion vaccines (AS01, AS03, or non-adjuvanted): Phase 1–2 RCT. Lancet Infectious Diseases (2022). doi:10.1016/S1473-3099(22)00024-X.
- Sacconnay L et al. RSVPreF3-AS01 vaccine elicits broad neutralization of contemporary and antigenically divergent RSV strains. Science Translational Medicine (2023). doi:10.1126/scitranslmed.adg6050.
I ‘m graduated in Medical Biology from the Catholic University of Louvain.
My passion lies in merging scientific expertise with strategic innovation to drive impactful advancements in healthcare and ensure GSK remains at the forefront of analytical science and manufacturing excellence.
As a global technical lead in analytical science, I oversee the development, validation, and deployement of cutting-edge methods for biological products, establish global standards, and drive harmonization across the GSK network. I collaborate with internal teams and external regulatory bodies to ensure compliance with evolving regulatory requirements, strengthen innovation, and position GSK as a leader in analytical science.
Throughout my career, I have held various leadership positions, including Product & Process Analytics Head, Project Manager and Scientist. My expertise spans preclinical models, vaccinology, virology, molecular biology, in vitro and in vivo assay development, flow cytometry, and bioinformatics tools.
I have contributed to preclinical immunology for viral vaccines, including immunogenicity and efficacy studies, toxicity assessments, and regulatory submissions. My work has supported Phase I/II clinical trials for the vaccines targeting pediatrics and older adults.
I’m author and co-author on several peer-reviewed articles in high-impact journals (Nature Communications, Science Translational Medicine, The Lancet Infectious Diseases, npj Vaccines, ImmunoHorizons) :
- Bouzya B et al. Immunogenicity of an AS01-adjuvanted RSVPreF3 vaccine in animal models. npj Vaccines (2023). doi:10.1038/s41541-023-00729-4.
- Stokes A H et al. Repeated dose toxicity and DART studies of an RSV candidate vaccine in rabbits and rats. International Journal of Toxicology (2021). doi:10.1177/1091581820985782.
- Folschweiller N et al. Reactogenicity, safety, and immunogenicity of chimeric HA influenza split-virion vaccines (AS01, AS03, or non-adjuvanted): Phase 1–2 RCT. Lancet Infectious Diseases (2022). doi:10.1016/S1473-3099(22)00024-X.
- Sacconnay L et al. RSVPreF3-AS01 vaccine elicits broad neutralization of contemporary and antigenically divergent RSV strains. Science Translational Medicine (2023). doi:10.1126/scitranslmed.adg6050.
I ‘m graduated in Medical Biology from the Catholic University of Louvain.
My passion lies in merging scientific expertise with strategic innovation to drive impactful advancements in healthcare and ensure GSK remains at the forefront of analytical science and manufacturing excellence.
